BRIEF-Elicio To Merge With A Wholly-Owned Unit Of Angion In An All-Stock Transaction
Reuters
Jan 17, 2023
Jan 17 (Reuters) - Angion Biomedica Corp :
* ANGION- MERGER TO RESULT IN NASDAQ-LISTED CO FOCUSED ON DEVELOPING IMMUNOTHERAPIES BASED ON ELICIO'S LYMPH NODE-TARGETING AMPHIPHILE (CORRECTS SOURCE)
* ELICIO THERAPEUTICS AND ANGION ENTER INTO DEFINITIVE MERGER AGREEMENT
* ELICIO WILL MERGE WITH A WHOLLY-OWNED UNIT OF ANGION IN AN ALL-STOCK TRANSACTION
* ANGION - CURRENT ANGION STOCKHOLDERS ARE EXPECTED TO OWN 34.5% OF NEWLY COMBINED COMPANY WHILE ELICIO STOCKHOLDERS WILL OWN 65.5% OF NEWLY COMBINED CO.
Source text for Eikon: [ID: nGNX38fS41] Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.